Will FDA issue warning or ban on compounded GLP-1 drugs by end of 2025? | Binary | | | 12 days ago | |
Will Zepbound price drop by 20% or more by June 30, 2025? | Binary | | | 12 days ago | |
Will Ro-Lilly partnership boost Zepbound prescriptions by 50% by end of 2025? | Binary | | | 12 days ago | |
Hims & Hers Health, Inc. stock recovers to pre-announcement level by Q1 2025? | Binary | | | 12 days ago | |
Will Ro's insurance tool for GLP-1 drugs be used by 1 million unique users by end of 2024? | Binary | | | 4 months ago | |
Will Ro report a 50% increase in monthly active users of their insurance tool by end of 2024? | Binary | | | 4 months ago | |
What will be the market share change between Zepbound and Wegovy by end of 2025? | Categorical | | | 12 days ago | |
How many new partnerships will Eli Lilly form for Zepbound by end of 2025? | Categorical | | | 12 days ago | |
Eli Lilly's Zepbound market share in weight-loss drugs by end of 2025? | Categorical | | | 12 days ago | |
Eli Lilly's Zepbound sales increase by more than 20% in Q1 2025? | Binary | | | 12 days ago | |
Ro faces legal challenges over Zepbound distribution by end of 2024? | Binary | | | 12 days ago | |
Leader in GLP-1 weight-loss drug market by end of 2025? | Categorical | | | 12 days ago | |
Impact of Ro's partnership with Eli Lilly on customer base by mid-2025? | Categorical | | | 12 days ago | |
Which age group will have the highest usage of Ro's insurance tool for GLP-1 drugs by end of 2024? | Categorical | | | 4 months ago | |
Which US region will have the highest usage of Ro's insurance tool for GLP-1 drugs by end of 2024? | Categorical | | | 4 months ago | |
Which GLP-1 drug will see the highest increase in insurance coverage by end of 2024? | Categorical | | | 4 months ago | |
Will a major insurance provider expand coverage for GLP-1 drugs by end of 2024? | Binary | | | 4 months ago | |
How will public opinion on GLP-1 drug affordability change by end of 2025? | Categorical | | | 12 days ago | |
